Life science incubator Paragon Biosciences grabs new CEO for investment arm
Biotech, digital health and medtech incubator Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital (PHC).
Biotech, digital health and medtech incubator Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital (PHC).
Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.
F2G has raised $60.8 million to fund late-phase clinical development of its antifungal agent olorofim and prepare for commercialization. The Cowen Healthcare Investments-led round comes four years after F2G raised a similar sum to take the dihydroorotate dehydrogenase inhibitor into phase 2b.
Roche has offloaded its anti-CSF1R monoclonal antibody emactuzumab to Celleron Therapeutics. The licensing deal comes almost two years after Roche dropped the tumor microenvironment modulator after putting it through a clutch of early-phase studies in solid tumor patients.
Charles River Labs has seen its revenue edge up despite COVID challenges as it looks to buy up cell therapy services provider Cellero.
After working in stealth since October, Perceptive Advisors is unveiling its latest biotech: LianBio, which serves the dual mission of bringing much-needed new drugs to China and helping U.S. biotech companies expand their operations into Asia.
Bayer has struck a $425 million upfront deal to buy KaNDy Therapeutics in the belief its treatment for menopause-related hot flashes has blockbuster potential. KaNDy recently completed a phase 2b trial of neurokinin-1,3 receptor antagonist NT-814, teeing it up to start a pivotal study next year.
After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs to help lead its new acquisition’s R&D.
Xcovery pitted its ALK inhibitor against Pfizer’s Xalkori—the first-ever FDA-approved drug in its class—and came out on top. The drug, ensartinib, shrank tumors in three-quarters of previously untreated lung cancer patients, compared to Xalkori’s 67%, and staved off cancer for two years, more than double the time Xalkori logged.
Seres Therapeutics has endured a tough few years of trials setbacks, cuts and new management, but the GI biotech is hoping with its new set of broadly positive late-stage data it can finally file for an approval.